A study of irbesartan/amlodipine on hypertensive patients

A study of irbesartan/amlodipine on hypertensive patients - AIMIX study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017785

Enrollment

Registered

2015-06-03

Start date

2013-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Irbesartan/Amloipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive patients

Exclusion criteria

Exclusion criteria: 1) Allergy to Irbesartan/Amloipine 2) Renal aretery stenosis of one or both sides 3) Severe liver dysfunction 4) Alcoholic or drug abuse 5) Pregnancy or nursing 6) Myocardial and cerebral infarction in three months 7) Blood tests are as follows. a) AST or ALT more than 2.5 folds or equal to standard values b) Total bilirubin more than or equal to 3.0 mg/dL c) Serum creatinine more than or equal to 2.5 mg/dL d) Serum potassium more than or equal to 5.0 mEq/L 8) Other inappropiate patients

Design outcomes

Primary

Measure	Time frame
Blood pressure change	—

Countries

Japan

Contacts

Public ContactOsamu Yasuda

Kumamoto University Department of Cardiology

o-yasuda@kumamoto-u.ac.jp096-373-5393

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026